Recently, China's Ministry of Industry and Information Technology (MIIT) announced the 2024 List of Biom Manufacturing Flagship Products (First Batch). A total of 36 flagship products were selected, covering multiple sub-sectors such as biomaterials, biochemicals, and biomedicine, fully demonstrating China's cutting-edge technological achievements in the field of biom manufacturing and setting benchmarks for future industrial development. Oryzogen's newly approved product, Aofumin®—Recombinant Human Albumin Injection (produced in rice)—was successfully selected, showcasing the company's outstanding R&D strength and market competitiveness in the biomedical field.
It is reported that the collection of biom manufacturing flagship products organized by MIIT aims to implement the spirit of the National Conference on Advancing New Industrialization, promote breakthroughs in original and disruptive technologies in the biom manufacturing sector, encourage the application of flagship products, accelerate the transformation of innovative achievements into practical productivity, and enhance the integrated development capability of "technology R&D – manufacturing – market promotion" in biom manufacturing. Following recommendations from provincial-level industrial and information technology authorities and expert evaluation processes, the "List of Biom Manufacturing Flagship Products (First Batch)" was formed.
As the first recombinant human albumin approved for marketing in China and the world's first recombinant human albumin produced using a plant expression system, Aofumin® has overcome challenges such as low yield in recombinant technology, complex purification processes, difficulties in scaling up production, high safety risks, and elevated costs. The launch of Aofumin® signifies that China's research in recombinant human albumin and plant bioreactor technology has reached an internationally leading position, breaking the long-standing dependence on imported human serum albumin, and holds significant strategic importance and social value.